X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PIRAMAL ENTERPRISES DISHMAN PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 25.1 38.6 64.9% View Chart
P/BV x 3.3 3.9 86.9% View Chart
Dividend Yield % 0.7 0.6 105.2%  

Financials

 DISHMAN PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PIRAMAL ENTERPRISES
Mar-16
DISHMAN PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs3741,065 35.2%   
Low Rs129805 16.0%   
Sales per share (Unadj.) Rs197.8383.0 51.6%  
Earnings per share (Unadj.) Rs21.255.1 38.5%  
Cash flow per share (Unadj.) Rs34.774.1 46.9%  
Dividends per share (Unadj.) Rs2.0017.50 11.4%  
Dividend yield (eoy) %0.81.9 42.5%  
Book value per share (Unadj.) Rs179.9719.9 25.0%  
Shares outstanding (eoy) m80.69172.56 46.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.4 52.1%   
Avg P/E ratio x11.917.0 69.9%  
P/CF ratio (eoy) x7.212.6 57.4%  
Price / Book Value ratio x1.41.3 107.7%  
Dividend payout %9.431.8 29.7%   
Avg Mkt Cap Rs m20,306161,344 12.6%   
No. of employees `0000.83.8 21.9%   
Total wages/salary Rs m5,35516,898 31.7%   
Avg. sales/employee Rs Th19,252.717,472.6 110.2%   
Avg. wages/employee Rs Th6,459.54,466.9 144.6%   
Avg. net profit/employee Rs Th2,064.12,512.8 82.1%   
INCOME DATA
Net Sales Rs m15,96166,099 24.1%  
Other income Rs m2652,425 10.9%   
Total revenues Rs m16,22668,524 23.7%   
Gross profit Rs m4,10318,723 21.9%  
Depreciation Rs m1,0913,274 33.3%   
Interest Rs m9449,388 10.1%   
Profit before tax Rs m2,3348,485 27.5%   
Minority Interest Rs m03 0.0%   
Prior Period Items Rs m11,593 0.1%   
Extraordinary Inc (Exp) Rs m0457 0.0%   
Tax Rs m6241,032 60.4%   
Profit after tax Rs m1,7119,506 18.0%  
Gross profit margin %25.728.3 90.8%  
Effective tax rate %26.712.2 219.7%   
Net profit margin %10.714.4 74.5%  
BALANCE SHEET DATA
Current assets Rs m11,01847,488 23.2%   
Current liabilities Rs m9,517104,362 9.1%   
Net working cap to sales %9.4-86.0 -10.9%  
Current ratio x1.20.5 254.4%  
Inventory Days Days11041 272.0%  
Debtors Days Days3551 68.1%  
Net fixed assets Rs m16,30426,532 61.5%   
Share capital Rs m161345 46.8%   
"Free" reserves Rs m12,907114,024 11.3%   
Net worth Rs m14,516124,221 11.7%   
Long term debt Rs m4,18975,812 5.5%   
Total assets Rs m29,805308,356 9.7%  
Interest coverage x3.51.9 182.3%   
Debt to equity ratio x0.30.6 47.3%  
Sales to assets ratio x0.50.2 249.8%   
Return on assets %8.96.1 145.4%  
Return on equity %11.87.7 154.0%  
Return on capital %17.510.0 176.0%  
Exports to sales %24.817.2 144.2%   
Imports to sales %3.76.6 56.6%   
Exports (fob) Rs m3,95611,362 34.8%   
Imports (cif) Rs m5964,364 13.7%   
Fx inflow Rs m4,95214,435 34.3%   
Fx outflow Rs m6975,183 13.4%   
Net fx Rs m4,2559,253 46.0%   
CASH FLOW
From Operations Rs m2,786-67,773 -4.1%  
From Investments Rs m-1,529-8,768 17.4%  
From Financial Activity Rs m-94176,199 -1.2%  
Net Cashflow Rs m316-342 -92.4%  

Share Holding

Indian Promoters % 61.4 52.9 116.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.0 92.5%  
FIIs % 12.7 26.6 47.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 16.5 133.9%  
Shareholders   46,261 93,274 49.6%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PLETHICO PHARMA  AJANTA PHARMA  UNICHEM LAB  ALKEM LABORATORIES  ELDER PHARMA  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Of Pharma Drug Approvals, Global Updates, Oil Prices, and Top Stocks in Action Today(Pre-Open)

Indian share markets snapped their losing streak seen during last week and closed their Wednesday session on a positive note.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - J.B.CHEMICALS COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS